{"filing":{"accession_number":"0001171843-26-006164","cik":"0002027329","ticker":"OPTHF","company_name":"Optimi Health Corp.","form":"6-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"f6k_092226.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2027329/000117184326006164/f6k_092226.htm"},"events":[{"id":34217,"run_id":31486,"accession_number":"0001171843-26-006164","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The press release announces the appointment of Dr. Michael Blough as Chief Clinical Development Officer, a newly created executive position. The appointment is material because Dr. Blough will oversee critical clinical development strategy for two pivotal trials (Phase 2 psilocybin for major depressive disorder and Phase 3 MDMA for PTSD) that are central to the company's regulatory pathway and value creation. His 20+ years of experience in clinical trials and established relationships with Health Canada directly support the company's near-term clinical milestones.","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-09-22","form":"6-K","submitted_at":null,"items":[{"id":37896,"accession_number":"0001171843-26-006164","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The press release announces the appointment of Dr. Michael Blough as Chief Clinical Development Officer, a newly created executive position. The appointment is material because Dr. Blough will oversee critical clinical development strategy for two pivotal trials (Phase 2 psilocybin for major depressive disorder and Phase 3 MDMA for PTSD) that are central to the company's regulatory pathway and value creation. His 20+ years of experience in clinical trials and established relationships with Health Canada directly support the company's near-term clinical milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-22T13:01:45.208525+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37896,"accession_number":"0001171843-26-006164","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The press release announces the appointment of Dr. Michael Blough as Chief Clinical Development Officer, a newly created executive position. The appointment is material because Dr. Blough will oversee critical clinical development strategy for two pivotal trials (Phase 2 psilocybin for major depressive disorder and Phase 3 MDMA for PTSD) that are central to the company's regulatory pathway and value creation. His 20+ years of experience in clinical trials and established relationships with Health Canada directly support the company's near-term clinical milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-22T13:01:45.208525+00:00","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-09-22"}]}